Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates.
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates.
复制标题
DOI：
10.2337/db13-0265
复制
发表时间：
2013-11
期刊：
影响因子：
7.7
通讯作者：
ACT NOW Study
中科院分区：
文献类型：
--
作者：
Defronzo RA;Tripathy D;Schwenke DC;Banerji M;Bray GA;Buchanan TA;Clement SC;Gastaldelli A;Henry RR;Kitabchi AE;Mudaliar S;Ratner RE;Stentz FB;Musi N;Reaven PD;ACT NOW Study
我们检查了441名糖耐量受损(IGT)受试者的代谢特征，这些受试者参与了ACT NOW研究，并在研究结束时进行了完整的代谢测量，这些受试者参与了2型糖尿病(T2 DM)的发展。受试者随机接受吡格列酮(PGZ；45毫克/天)或安慰剂治疗，观察时间中位数为2.4年。计算胰岛素敏感性指数(松田指数[MI])、胰岛素分泌(IS)/胰岛素抵抗(IR；ΔI0~120/ΔG0~120，ΔIS Rate[ISR]0~120/ΔG0~120)和β细胞功能(ΔI/ΔG×MI和ΔISR/ΔG×MI)。45名服用安慰剂的受试者与15名服用PGZ的受试者发生糖尿病(优势比[OR]0.28[95%可信区间0.15-0.49]；P<；0.0001)；48%的服用安慰剂的受试者恢复正常糖耐量，而安慰剂组为28%(P<；0.005)。较高的最终糖耐量状态(NGT和GT；IGT和GT；T2 DM)与胰岛素敏感性(OR0.61[95%CI0.54-0.80])、IS(OR0.61[95%CI0.50-0.75])和β细胞功能(lnIS/IR指数和lnISR/IR指数)(OR0.26[95%CI0.19-0.37]；均P<；0.0001)的改善有关。在测量的因素中，β细胞功能的改善与最终的糖耐量状态关系最密切。
We examined the metabolic characteristics that attend the development of type 2 diabetes (T2DM) in 441 impaired glucose tolerance (IGT) subjects who participated in the ACT NOW Study and had complete end-of-study metabolic measurements. Subjects were randomized to receive pioglitazone (PGZ; 45 mg/day) or placebo and were observed for a median of 2.4 years. Indices of insulin sensitivity (Matsuda index [MI]), insulin secretion (IS)/insulin resistance (IR; ΔI0–120/ΔG0–120, ΔIS rate [ISR]0–120/ΔG0–120), and β-cell function (ΔI/ΔG × MI and ΔISR/ΔG × MI) were calculated from plasma glucose, insulin, and C-peptide concentrations during oral glucose tolerance tests at baseline and study end. Diabetes developed in 45 placebo-treated vs. 15 PGZ-treated subjects (odds ratio [OR] 0.28 [95% CI 0.15–0.49]; P < 0.0001); 48% of PGZ-treated subjects reverted to normal glucose tolerance (NGT) versus 28% of placebo-treated subjects (P < 0.005). Higher final glucose tolerance status (NGT > IGT > T2DM) was associated with improvements in insulin sensitivity (OR 0.61 [95% CI 0.54–0.80]), IS (OR 0.61 [95% CI 0.50–0.75]), and β-cell function (ln IS/IR index and ln ISR/IR index) (OR 0.26 [95% CI 0.19–0.37]; all P < 0.0001). Of the factors measured, improved β-cell function was most closely associated with final glucose tolerance status.
登录
查看更多内容
影响因子：
3.8
作者：
Abdul-Ghani, Muhammad A.;Molina-Carrion, Marjorie;DeFronzo, Ralph A.
通讯作者：
DeFronzo, Ralph A.
影响因子：
2.7
作者：
DeFronzo, Ralph A.;Banerji, MaryAnn;Tripathy, Devjit
通讯作者：
Tripathy, Devjit
影响因子：
7.7
作者：
Kim, SH;Abbasi, F;Reaven, GM
通讯作者：
Reaven, GM
影响因子：
168.9
作者：
Dormandy, JA;Charbonnel, B;Taton, J
通讯作者：
Taton, J
影响因子：
16.2
作者：
Cowie, Catherine C.;Engelgau, Michael M.;Gregg, Edward W.
通讯作者：
Gregg, Edward W.